A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft
Information source: Cunningham, Derek N., O.D., P.A.
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Allergic Conjunctivitis
Phase: N/A
Status: Recruiting
Sponsored by: Cunningham, Derek N., O.D., P.A. Official(s) and/or principal investigator(s):
Derek Cunningham, OD, Principal Investigator, Affiliation: Dell Laser Consultants
Overall contact:
Derek Cunningham, OD, Phone: 512.347.0255, Email: dcunningham@dellvision.com
Summary
The purpose of this study is to evaluate the comfort of BEPREVE compared to LASTACAFT after
instillation.
Clinical Details
Official title: A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft in Patients With a History of Allergic Conjunctivitis
Study design: Observational Model: Case Control, Time Perspective: Prospective
Detailed description:
After one drop is instilled subjects will complete a comfort assessment at 1, 3, 5, and 10
minutes after drop instillation.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Each patient must meet the following criteria to be enrolled in this study:
1. Are male or female at least 18 years of age who are diagnosed with allergic
conjunctivitis.
2. Have allergic ocular symptoms within the last three days.
3. Are willing/able to follow instructions from the study investigator and his/her
staff.
4. Have signed informed consent approved by Institutional Review Board or Independent
Ethics Committee.
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from the study:
1. Have known hypersensitivity to either BEPREVE™ or LASTACAFT® or to any component of
the test article (including "procedural" medications such as anesthetic and/or
fluorescein drops, dilating drops, etc.).
2. Have active corneal pathology noted in the study eye at the screening visit. Active
corneal pathology is defined as corneal pathology that is non stable, or greater than
mild, or will compromise assessment of the safety or efficacy of treatment.
3. Are pregnant or nursing/lactating.
Locations and Contacts
Derek Cunningham, OD, Phone: 512.347.0255, Email: dcunningham@dellvision.com
Derek Cunningham, 901 S. Mopac Expy, Bldg. 4, Suite 350, Texas 78746, United States; Recruiting
Derek Cunningham, OD, Phone: 512.347.0255, Email: dcunningham@dellvision.com
Additional Information
Starting date: April 2011
Last updated: April 19, 2011
|
